Tissue Factor and Cancer Stem Cells
Open Access
- 1 December 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 29 (12) , 2005-2014
Abstract
A common feature in the progression of multiple human malignancies is the protracted deregulation of the coagulation system, often referred to as cancer coagulopathy. Indeed, cancer cells and their vascular stroma often exhibit procoagulant properties, of which deregulation of tissue factor (TF) expression is a notable, although not the sole example. These changes can be traced to oncogenic influences affecting epidermal growth factor receptor (EGFR), EGFRvIII, K-ras, p53, PTEN, and probably many other proto-oncogenes and tumor suppressors in tumor parenchyma. Cancer stem cells (CSCs)/tumor initiating cells (TICs) are thought to represent the primary target and the main cellular effector through which oncogenic mutations exert their tumor-inducing effects. In so doing, CSCs/TICs depend on interactions with the tumor vasculature, which forms supportive niches for their clonal growth. We postulate that TF contributes to these interactions (directly or indirectly) through procoagulant and signaling effects, the latter executed in concert with juxtaposed protease activated receptors (mainly PAR-1 and PAR-2). TF/PAR system acts as a “blood sensing” mechanism, whereby cancer cells, including CSCs/TICs, may respond to plasma proteases (Factors VIIa, Xa, and IIa) and their related microenvironmental changes (fibrin deposition, activation of platelets). A growing body of still largely circumstantial evidence suggests that these events may contribute to the CSC/TIC niche, which could influence tumor initiation, metastasis, recurrence, and therapeutic intractability. Indeed, certain types of cancer cells harboring markers of CSCs (CD133) exhibit elevated TF expression and depend on this receptor to efficiently initiate tumor growth. We propose that both tumor cell–associated and host-related TF could influence the properties of CSCs, and that agents targeting the TF/PAR system may represent a hitherto unappreciated therapeutic opportunity to control cancer progression by influencing the CSC/TIC compartment.Keywords
This publication has 89 references indexed in Scilit:
- Effects of Ectopic Nanog and Oct4 Overexpression on Mesenchymal Stem CellsStem Cells and Development, 2009
- Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFRProceedings of the National Academy of Sciences, 2009
- Looking ahead in cancer stem cell researchNature Biotechnology, 2009
- Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformationNature, 2008
- The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cellsJournal of Molecular Medicine, 2008
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- Triggers, targets and treatments for thrombosisNature, 2008
- A core Klf circuitry regulates self-renewal of embryonic stem cellsNature Cell Biology, 2008
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003
- The Hallmarks of CancerCell, 2000